Nutrition
Volume 25, Issue 2 , Pages 172-181 , February 2009

Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease

  • Luzia Valentini, Ph.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-30-450-514-113; fax: +49-30-450-514-923
    • ,
  • Eva Katrin Wirth, M.Sc.

      Affiliations

    • Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Ulrich Schweizer, Ph.D.

      Affiliations

    • Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Susanne Hengstermann, Ph.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Lennart Schaper, M.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Thomas Koernicke, M.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Ekkehart Dietz, Ph.D.

      Affiliations

    • Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Kristina Norman, Ph.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Carsten Buning, M.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Brigitte M. Winklhofer-Roob, M.D., Ph.D.

      Affiliations

    • Human Nutrition and Metabolism Research and Training Centre, Karl-Franzens University, Graz, Austria
    • ,
  • Herbert Lochs, M.D., Ph.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Johann Ockenga, M.D., Ph.D.

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Campus Mitte, Charité–Universitätsmedizin Berlin, Berlin, Germany

Received 16 January 2008 ,Accepted 25 July 2008.

References 

  1. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783
  2. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443–477
  3. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther. 2006;23:1511–1523
  4. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89:447–452
  5. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol. 2006;3:29–34
  6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867
  7. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–2921
  8. Kralisch S, Sommer G, Deckert CM, Linke A, Bluher M, Stumvoll M, et al. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol. 2007;32:161–171
  9. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS. 2007;21:895–904
  10. Toussirot E, Streit G, Wendling D. The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem. 2007;14:1095–1100
  11. Taskapan MC, Taskapan H, Sahin I, Keskin L, Atmaca H, Ozyalin F. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail. 2007;29:147–154
  12. Ockenga J, Bischoff SC, Tillmann HL, Rifai K, Widjaja A, Boker KH, et al. Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology. 2000;119:1656–1662
  13. Ockenga J, Tietge UJ, Boker KH, Manns MP, Brabant G, Bahr MJ. Distinct roles of free leptin, bound leptin and soluble leptin receptor during the metabolic-inflammatory response in patients with liver cirrhosis. Aliment Pharmacol Ther. 2007;25:1301–1309
  14. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999;117:73–81
  15. Valentini L, Buning C, Hengstermann S, Schaper L, Koernicke T, Norman K, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition. 2008;24:694–702
  16. Ahualli J. The fat halo sign. Radiology. 2007;242:945–946
  17. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut. 2007;56:577–583
  18. Schaffler A, Herfarth H. Creeping fat in Crohn's disease: travelling in a creeper lane of research?. Gut. 2005;54:742–744
  19. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index (National Cooperative Crohn's Disease Study). Gastroenterology. 1976;70:439–444
  20. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845
  21. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1(8167):514
  22. Sattler W, Puhl H, Hayn M, Kostner GM, Esterbauer H. Determination of fatty acids in the main lipoprotein classes by capillary gas chromatography: BF3/methanol transesterification of lyophilized samples instead of Folch extraction gives higher yields. Anal Biochem. 1991;198:184–190
  23. Pirlich M, Schutz T, Spachos T, Ertl S, Weiss ML, Lochs H, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology. 2000;32:1208–1215
  24. Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein–calorie malnutrition in liver cirrhosis. Clin Investig. 1992;70:478–486
  25. Kushner RF, Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr. 1986;44:417–424
  26. Sitaraman S, Liu X, Charrier L, Gu LH, Ziegler TR, Gewirtz A, et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J. 2004;18:696–698
  27. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–105
  28. Nishi Y, Isomoto H, Ueno H, Ohnita K, Wen CY, Takeshima F, et al. Plasma leptin and ghrelin concentrations in patients with Crohn's disease. World J Gastroenterol. 2005;11:7314–7317
  29. Paul G, Schaffler A, Neumeier M, Furst A, Bataillle F, Buechler C, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis. 2006;12:471–477
  30. Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut. 2005;54:789–796
  31. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–1758
  32. Kloting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6:79–87
  33. Muoio DM, Newgard CB. Metabolism: A is for adipokine. Nature. 2005;436(7049):337–338
  34. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–175
  35. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E–deficient mice. Circulation. 2002;106:2767–2770
  36. Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:53–56
  37. Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, et al. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand J Gastroenterol. 2004;39:650–656
  38. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3:185–193
  39. Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, et al. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab. 2003;88:5468–5472
  40. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:209–217
  41. Heslin MJ, Newman E, Wolf RF, Pisters PW, Brennan MF. Effect of hyperinsulinemia on whole body and skeletal muscle leucine carbon kinetics in humans. Am J Physiol Endocrinol Metab. 1992;262(pt 1):E911–E918
  42. Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care. 2007;10:511–517
  43. Langhorst J, Eisenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninviasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and OMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169
  44. Nordberg E, Schaufelberger C, Bosaeus I. The effect of glucocorticoids on fat and lean tissue masses in giant cell arteritis. Scand J Rheumatol. 1998;27:106–111
  45. Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisolone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metabol. 1998;83:3795–3802

 The study was funded by grants 89434169 and 89434160 from the Charité–Universitätsmedizin Berlin.

PII: S0899-9007(08)00346-8

doi: 10.1016/j.nut.2008.07.020

Nutrition
Volume 25, Issue 2 , Pages 172-181 , February 2009

Article Tools

* Image Usage & Resolution